Neoadjuvant Carboplatin in Triple Negative Breast Cancer

Plain-language summary

This study evaluates neoadjuvant (before-surgery) Carboplatin treatment together with Doxorubicin, Paclitaxel and Cyclophosphamide in patients with triple negative breast cancer. It enrolled patients with stage II or III triple negative breast cancer. The study was carried out in Phase 2 and has been completed.

The summary above is a plain-language rendering of the official record. The original English title is shown for reference.

Trial details

Phase

Phase 2

Status

Completed

Sponsor

Barretos Cancer Hospital

Intervention

Doxorubicin, Carboplatin, Paclitaxel, Cyclophosphamide

Start date

5/17/2017

Estimated completion

10/22/2021

Countries

Brazil

Related genes

Locations

• Barretos, Brazil

Eligibility criteria

Criteria are reproduced from the ClinicalTrials.gov record in the original English. Only the trial team can determine eligibility.

Inclusion Criteria:

* Triple Negative Breast Cancer;
* Stage II or III;
* Performance Status ECOG \<2 or Karnofsky \>50%;
* Hematologic (minimal values):

Absolute neutrophil count \> 1,500/mm3 Hemoglobin \> 10.0 g/dl Platelet count \> 100,000/mm3

Exclusion Criteria:

* Stage I or IV;
* other malignancies.